{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:21Z","timestamp":1791910641153,"version":"4.3.4"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Vancomycin is a commonly used antibiotic in critically ill patients with severe methicillin-resistant Staphylococcus aureus infections. Due to its narrow therapeutic window, under- or overdosing is likely to result in adverse effects, especially in patients with conditions associated with altered pharmacokinetics such as obesity. The objective of this study was to investigate the impact of obesity on serum concentrations of vancomycin in critically ill patients receiving intravenous vancomycin by continuous infusion based on ideal body weight (IBW). Methods: This retrospective observational study performed at the University Hospital of Leipzig, Germany, included all patients admitted to the intensive care unit (ICU) between January 2009 and December 2015 who received guideline-based vancomycin therapy based on IBW. Serum concentrations were obtained through routinely performed therapeutic drug monitoring (TDM). Results: A total of 1066 patients with a median age of 62 years were included in this study. The median (25%; 75% quantile) vancomycin treatment duration was 4 (2; 7) days and the median time to reach target concentrations of 20\u201325 mg L\u22121 was 3 (2; 4) days without a significant difference between BMI groups. Overall, only 25.9% of patients were in the therapeutic range of 20\u201325 mg L\u22121 in the entire treatment interval. 47.8% of vancomycin concentrations obtained from TDM were below the desired target range with no differences between the BMI groups (p = 0.077). 26.3% of measurements exceeded the target range, with a significant increase in the morbidly obese group (p &lt; 0.001). A higher BMI was associated with an increased ICU, in-hospital, 28- and 90-day mortality in morbidly obese patients (p &lt; 0.05). Age, BMI and high SAPS-II and SOFA scores were significant predictors of an increased risk of death. Conclusions: Our preliminary findings suggest that IBW-based dosing may help reduce the risk of supratherapeutic concentrations in morbidly obese patients. The high rates of sub- and supratherapeutic vancomycin serum concentrations across all patients highlight the need for close TDM and dose adjustments, particularly in morbidly obese patients with the highest rates of supratherapeutic vancomycin serum concentrations and of RRT.<\/jats:p>","DOI":"10.3390\/antibiotics14090895","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:51:21Z","timestamp":1757065881000},"page":"895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Obesity on Serum Concentrations of Vancomycin Administered as Continuous Infusion and on Clinical Outcomes in Critically Ill Patients\u2014A Retrospective Observational Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0981-2231","authenticated-orcid":false,"given":"Stefanie","family":"Nothofer","sequence":"first","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-6499","authenticated-orcid":false,"given":"Rico","family":"Angeli","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"},{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Weiss","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-0094","authenticated-orcid":false,"given":"Christian","family":"Dumps","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-1363","authenticated-orcid":false,"given":"Felix","family":"Berger","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephin","family":"Eckert","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"},{"name":"Department of Anaesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Bergmannstrost Hospital Halle, 06112 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Girrbach","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"},{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadin","family":"Scheidt","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Menzel","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Wrigge","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Bergmannstrost Hospital Halle, 06112 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-3254","authenticated-orcid":false,"given":"Philipp","family":"Simon","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany"},{"name":"Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(06)70523-0","article-title":"Obesity and infection","volume":"6","author":"Falagas","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41366-021-01035-6","article-title":"Obesity and infectious diseases: Pathophysiology and epidemiology of a double pandemic condition","volume":"46","author":"Pugliese","year":"2022","journal-title":"Int. J. Obes."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","article-title":"Drug disposition in obesity: Toward evidence-based dosing","volume":"55","author":"Knibbe","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.2367","article-title":"Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock","volume":"40","author":"Masich","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the Clinical Use of Vancomycin","volume":"60","author":"Molina","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/IDR.S121513","article-title":"The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock","volume":"9","author":"Katip","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","article-title":"Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jiph.2015.01.011","article-title":"Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application","volume":"8","author":"Tafelski","year":"2015","journal-title":"J. Infect. Public Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2015.04.013","article-title":"Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion","volume":"46","author":"Hanrahan","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/1060028017720946","article-title":"Intravenous Vancomycin Associated with the Development of Nephrotoxicity in Patients with Class III Obesity","volume":"51","author":"Choi","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/00185787231172388","article-title":"The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients with Obesity","volume":"58","author":"Wuerger","year":"2023","journal-title":"Hosp. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2146\/ajhp110324","article-title":"Performance of a vancomycin dosage regimen developed for obese patients","volume":"69","author":"Reynolds","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kubiak, D.W., Alquwaizani, M., Sansonetti, D., Barra, M.E., and Calderwood, M.S. (2015). An Evaluation of Systemic Vancomycin Dosing in Obese Patients. Open Forum Infect. Dis., 2.","DOI":"10.1093\/ofid\/ofv176"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372.","DOI":"10.1136\/bmj.n71"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Assadoon, M.S., Pearson, J.C., Kubiak, D.W., Kovacevic, M.P., and Dionne, B.W. (2022). Evaluation of Vancomycin Accumulation in Patients with Obesity. Open Forum Infect. Dis., 9.","DOI":"10.1093\/ofid\/ofac491"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jiac.2015.03.007","article-title":"The association of elevated trough serum vancomycin concentrations with obesity","volume":"21","author":"Richardson","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/sur.2014.198","article-title":"Vancomycin-Associated Nephrotoxicity: The Obesity Factor","volume":"16","author":"Davies","year":"2015","journal-title":"Surg. Infect."},{"key":"ref_24","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: A review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hotchkiss, R.S., Moldawer, L.L., Opal, S.M., Reinhart, K., Turnbull, I.R., and Vincent, J.L. (2016). Sepsis and septic shock. Nat. Rev. Dis. Primers, 2.","DOI":"10.1038\/nrdp.2016.45"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jarczak, D., Kluge, S., and Nierhaus, A. (2021). Sepsis-Pathophysiology and Therapeutic Concepts. Front. Med., 8.","DOI":"10.3389\/fmed.2021.628302"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.medin.2023.08.010","article-title":"Association of obesity on the outcome of critically ill patients affected by COVID-19","volume":"48","author":"Rodriguez","year":"2024","journal-title":"Med. Intensiva"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: Individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global","year":"2016","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pepper, D.J., Sun, J., Welsh, J., Cui, X., Suffredini, A.F., and Eichacker, P.Q. (2016). Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: A systematic review and meta-analysis. Crit. Care, 20.","DOI":"10.1186\/s13054-016-1360-z"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00134-019-05594-1","article-title":"Obesity in the critically ill: A narrative review","volume":"45","author":"Schetz","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1007\/s00134-009-1424-5","article-title":"The impact of obesity on outcomes after critical illness: A meta-analysis","volume":"35","author":"Hogue","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The Emperor\u2019s New Clothes: Prospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among Adult Hospitalized Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","unstructured":"World Health Organization (WHO) (2016). Obesity and Overweight 2016, World Health Organization (WHO)."},{"key":"ref_35","unstructured":"Kluge, H.H.P. (2022). WHO European Regional Obesity Report 2022, World Health Organization."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:41Z","timestamp":1760035181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antibiotics14090895"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14090895","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}